A meta-analysis of 13 randomized trials found immune checkpoint inhibitors do not improve overall survival in unselected patients with advanced ovarian cancer, challenging the broad expansion of immunotherapy in this setting. The analysis evaluated survival outcomes across heterogeneous trial populations, without demonstrating a significant benefit for the overall cohort. The result lands as ovarian cancer remains an area of active immune exploration, but the new synthesis implies that response signals may be confined to narrower biomarker-selected groups rather than the overall advanced population. For clinicians and developers, it reinforces the need to sharpen patient selection and endpoints beyond conventional survival readouts. The study also highlights how pooling trial data can clarify whether negative signals persist across designs—an approach increasingly relevant as checkpoint therapy studies mature in solid tumors.